undamentalytics Newsletter
Sign in

Bionexus Gene Lab Corp income statement

In fiscal 2025, Bionexus Gene Lab Corp reported revenue of $7.4m, down 21.9% on the year before, operating income of −$3.0m (a -39.9% margin) and net income of −$3.0m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue00111311101073
Cost of revenue−001011108863
Gross profit002211110
Research and development—————0000
Selling and marketing—————1221
General and administrative−001122221
Operating income0−011−0−3−2−3−3
Interest expense————00———
Net interest income————00———
Provision for credit losses—————−1−1−0—
Income before tax———1−0−3−2−3−3
Income tax−00—−0−0−0−000
Net income0−011−0−3−2−3−3
Diluted EPS$0.00$0.00$0.12——−$0.17−$0.09——
Diluted shares (average)7m9m10m——16m18m——
EBITDA0−011−0−3−1−3−2

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BGLC vs QSIBGLC vs SEERBGLC vs YDES

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Bionexus Gene Lab Corp's SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bionexus Gene Lab Corp.